Media stories about ANI Pharmaceuticals (NASDAQ:ANIP) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ANI Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 45.8993996766727 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

ANI Pharmaceuticals (NASDAQ ANIP) opened at $64.45 on Tuesday. The company has a market capitalization of $751.04, a price-to-earnings ratio of 100.70 and a beta of 2.90. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.45 and a quick ratio of 2.39. ANI Pharmaceuticals has a 12 month low of $42.23 and a 12 month high of $74.70.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The business had revenue of $48.16 million for the quarter, compared to analysts’ expectations of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The firm’s revenue was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.09 earnings per share. equities analysts forecast that ANI Pharmaceuticals will post 3.59 EPS for the current year.

ANIP has been the topic of several research analyst reports. Canaccord Genuity set a $77.00 price target on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Friday. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 4th. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th. BidaskClub cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a research note on Tuesday, November 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $71.00.

TRADEMARK VIOLATION NOTICE: This piece was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://theolympiareport.com/2018/01/02/ani-pharmaceuticals-anip-getting-somewhat-positive-press-coverage-study-finds.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.